Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial

Jorge E. Cortes, Dong Wook Kim, Hagop M. Kantarjian, Tim H. Brümmendorf, Irina Dyagil, Laimonas Griskevicius, Hemant Malhotra, Christine Powell, Karïn Gogat, Athena M. Countouriotis, Carlo Gambacorti-Passerini

Research output: Contribution to journalArticle

Abstract

Purpose: Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML). Patients and Methods: A total of 502 patients were randomly assigned 1:1 to bosutinib 500 mg per day or imatinib 400 mg per day. Results: The complete cytogenetic response (CCyR) rate at 12 months was not different for bosutinib (70%; 95% CI, 64% to 76%) versus imatinib (68%; 95% CI, 62% to 74%; two-sided P = .601); therefore, the study did not achieve its primary end point. The major molecular response (MMR) rate at 12 months was higher with bosutinib (41%; 95% CI, 35% to 47%) compared with imatinib (27%; 95% CI, 22% to 33%; two-sided P < .001). Time to CCyR and MMR was faster with bosutinib compared with imatinib (two-sided P < .001 for both). On-treatment transformation to accelerated/blast phase occurred in four patients (2%) on bosutinib compared with 10 patients (4%) on imatinib. A total of three CML-related deaths occurred on the bosutinib arm compared with eight on the imatinib arm. The safety profiles of bosutinib and imatinib were distinct; GI and liver-related events were more frequent with bosutinib, whereas neutropenia, musculoskeletal disorders, and edema were more frequent with imatinib. Conclusion: This ongoing trial did not meet its primary end point of CCyR at 12 months, despite the observed higher MMR rate at 12 months, faster times to CCyR and MMR, fewer on-treatment transformations to accelerated/blast phase, and fewer CML-related deaths with bosutinib compared with imatinib. Each drug had a distinct safety profile.

Original languageEnglish (US)
Pages (from-to)3486-3492
Number of pages7
JournalJournal of Clinical Oncology
Volume30
Issue number28
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Blast Crisis
Safety
Imatinib Mesylate
bosutinib
src-Family Kinases
Neutropenia
Edema

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cortes, J. E., Kim, D. W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., ... Gambacorti-Passerini, C. (2012). Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. Journal of Clinical Oncology, 30(28), 3486-3492. https://doi.org/10.1200/JCO.2011.38.7522

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : Results from the BELA trial. / Cortes, Jorge E.; Kim, Dong Wook; Kantarjian, Hagop M.; Brümmendorf, Tim H.; Dyagil, Irina; Griskevicius, Laimonas; Malhotra, Hemant; Powell, Christine; Gogat, Karïn; Countouriotis, Athena M.; Gambacorti-Passerini, Carlo.

In: Journal of Clinical Oncology, Vol. 30, No. 28, 01.10.2012, p. 3486-3492.

Research output: Contribution to journalArticle

Cortes, JE, Kim, DW, Kantarjian, HM, Brümmendorf, TH, Dyagil, I, Griskevicius, L, Malhotra, H, Powell, C, Gogat, K, Countouriotis, AM & Gambacorti-Passerini, C 2012, 'Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial', Journal of Clinical Oncology, vol. 30, no. 28, pp. 3486-3492. https://doi.org/10.1200/JCO.2011.38.7522
Cortes, Jorge E. ; Kim, Dong Wook ; Kantarjian, Hagop M. ; Brümmendorf, Tim H. ; Dyagil, Irina ; Griskevicius, Laimonas ; Malhotra, Hemant ; Powell, Christine ; Gogat, Karïn ; Countouriotis, Athena M. ; Gambacorti-Passerini, Carlo. / Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia : Results from the BELA trial. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 28. pp. 3486-3492.
@article{5774a8291d4d4e1a92087843e863ff1a,
title = "Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial",
abstract = "Purpose: Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML). Patients and Methods: A total of 502 patients were randomly assigned 1:1 to bosutinib 500 mg per day or imatinib 400 mg per day. Results: The complete cytogenetic response (CCyR) rate at 12 months was not different for bosutinib (70{\%}; 95{\%} CI, 64{\%} to 76{\%}) versus imatinib (68{\%}; 95{\%} CI, 62{\%} to 74{\%}; two-sided P = .601); therefore, the study did not achieve its primary end point. The major molecular response (MMR) rate at 12 months was higher with bosutinib (41{\%}; 95{\%} CI, 35{\%} to 47{\%}) compared with imatinib (27{\%}; 95{\%} CI, 22{\%} to 33{\%}; two-sided P < .001). Time to CCyR and MMR was faster with bosutinib compared with imatinib (two-sided P < .001 for both). On-treatment transformation to accelerated/blast phase occurred in four patients (2{\%}) on bosutinib compared with 10 patients (4{\%}) on imatinib. A total of three CML-related deaths occurred on the bosutinib arm compared with eight on the imatinib arm. The safety profiles of bosutinib and imatinib were distinct; GI and liver-related events were more frequent with bosutinib, whereas neutropenia, musculoskeletal disorders, and edema were more frequent with imatinib. Conclusion: This ongoing trial did not meet its primary end point of CCyR at 12 months, despite the observed higher MMR rate at 12 months, faster times to CCyR and MMR, fewer on-treatment transformations to accelerated/blast phase, and fewer CML-related deaths with bosutinib compared with imatinib. Each drug had a distinct safety profile.",
author = "Cortes, {Jorge E.} and Kim, {Dong Wook} and Kantarjian, {Hagop M.} and Br{\"u}mmendorf, {Tim H.} and Irina Dyagil and Laimonas Griskevicius and Hemant Malhotra and Christine Powell and Kar{\"i}n Gogat and Countouriotis, {Athena M.} and Carlo Gambacorti-Passerini",
year = "2012",
month = "10",
day = "1",
doi = "10.1200/JCO.2011.38.7522",
language = "English (US)",
volume = "30",
pages = "3486--3492",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

TY - JOUR

T1 - Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

T2 - Results from the BELA trial

AU - Cortes, Jorge E.

AU - Kim, Dong Wook

AU - Kantarjian, Hagop M.

AU - Brümmendorf, Tim H.

AU - Dyagil, Irina

AU - Griskevicius, Laimonas

AU - Malhotra, Hemant

AU - Powell, Christine

AU - Gogat, Karïn

AU - Countouriotis, Athena M.

AU - Gambacorti-Passerini, Carlo

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Purpose: Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML). Patients and Methods: A total of 502 patients were randomly assigned 1:1 to bosutinib 500 mg per day or imatinib 400 mg per day. Results: The complete cytogenetic response (CCyR) rate at 12 months was not different for bosutinib (70%; 95% CI, 64% to 76%) versus imatinib (68%; 95% CI, 62% to 74%; two-sided P = .601); therefore, the study did not achieve its primary end point. The major molecular response (MMR) rate at 12 months was higher with bosutinib (41%; 95% CI, 35% to 47%) compared with imatinib (27%; 95% CI, 22% to 33%; two-sided P < .001). Time to CCyR and MMR was faster with bosutinib compared with imatinib (two-sided P < .001 for both). On-treatment transformation to accelerated/blast phase occurred in four patients (2%) on bosutinib compared with 10 patients (4%) on imatinib. A total of three CML-related deaths occurred on the bosutinib arm compared with eight on the imatinib arm. The safety profiles of bosutinib and imatinib were distinct; GI and liver-related events were more frequent with bosutinib, whereas neutropenia, musculoskeletal disorders, and edema were more frequent with imatinib. Conclusion: This ongoing trial did not meet its primary end point of CCyR at 12 months, despite the observed higher MMR rate at 12 months, faster times to CCyR and MMR, fewer on-treatment transformations to accelerated/blast phase, and fewer CML-related deaths with bosutinib compared with imatinib. Each drug had a distinct safety profile.

AB - Purpose: Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared bosutinib with imatinib in newly diagnosed, chronic-phase chronic myeloid leukemia (CML). Patients and Methods: A total of 502 patients were randomly assigned 1:1 to bosutinib 500 mg per day or imatinib 400 mg per day. Results: The complete cytogenetic response (CCyR) rate at 12 months was not different for bosutinib (70%; 95% CI, 64% to 76%) versus imatinib (68%; 95% CI, 62% to 74%; two-sided P = .601); therefore, the study did not achieve its primary end point. The major molecular response (MMR) rate at 12 months was higher with bosutinib (41%; 95% CI, 35% to 47%) compared with imatinib (27%; 95% CI, 22% to 33%; two-sided P < .001). Time to CCyR and MMR was faster with bosutinib compared with imatinib (two-sided P < .001 for both). On-treatment transformation to accelerated/blast phase occurred in four patients (2%) on bosutinib compared with 10 patients (4%) on imatinib. A total of three CML-related deaths occurred on the bosutinib arm compared with eight on the imatinib arm. The safety profiles of bosutinib and imatinib were distinct; GI and liver-related events were more frequent with bosutinib, whereas neutropenia, musculoskeletal disorders, and edema were more frequent with imatinib. Conclusion: This ongoing trial did not meet its primary end point of CCyR at 12 months, despite the observed higher MMR rate at 12 months, faster times to CCyR and MMR, fewer on-treatment transformations to accelerated/blast phase, and fewer CML-related deaths with bosutinib compared with imatinib. Each drug had a distinct safety profile.

UR - http://www.scopus.com/inward/record.url?scp=84866175467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866175467&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.38.7522

DO - 10.1200/JCO.2011.38.7522

M3 - Article

C2 - 22949154

AN - SCOPUS:84866175467

VL - 30

SP - 3486

EP - 3492

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 28

ER -